Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Dana Portenier

Surgery Durham, NC Medical Doctor

NPI 1619051505 CMS profile 380398

2100 Erwin Rd, Durham, NC 27705

Open in the dashboard

General payments

$702,021

813 records reported · program years 2019–2025

Research payments

$50,581

Paid to them · 14 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Dana Portenier of Durham, NC is reported in the CMS Open Payments database as having received $702,021 across 813 general payments and $50,581 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

10 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $152,145 138
2024 General $188,325 191
2023 General $95,659 107
2022 General $52,586 60
2021 General $94,005 130
2021 Research $35,949 10
2020 General $61,200 73
2020 Research $4,000 1
2019 General $58,102 114
2019 Research $10,632 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Dana Portenier
  • Surgery median
  • Middle half of Surgery
  • National median

In program year 2025, general payments to Dana Portenier were reported at $152,145. Among 17,702 Surgery profiles paid that year, the median was $280 and the middle half received between $91 and $1,259.

Show as a table
Year Dana Portenier Surgery median Middle half National median
2019 $58,102 $253 $82–$1,521 $163
2020 $61,200 $131 $40–$706 $114
2021 $94,005 $168 $50–$904 $132
2022 $52,586 $224 $76–$1,218 $149
2023 $95,659 $253 $82–$1,255 $160
2024 $188,325 $279 $90–$1,381 $164
2025 $152,145 $280 $91–$1,259 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $277,835 158 payments
  2. Lilly USA, LLC $198,452 212 payments
  3. Medtronic, Inc. $148,716 261 payments
  4. Covidien LP $45,694 113 payments
  5. W. L. Gore & Associates, Inc. $11,304 18 payments
  6. Teleflex LLC $6,546 4 payments
  7. Eli Lilly and Company $5,400 3 payments
  8. RedHill Biopharma Inc. $2,775 1 payment
  9. Baxter Healthcare $2,188 4 payments
  10. Intuitive Surgical, Inc. $1,766 15 payments
  11. Other $1,345 24 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $523,107 209 payments
  2. Consulting Fee $73,868 19 payments
  3. Travel and Lodging $67,080 200 payments
  4. Food and Beverage $22,000 379 payments
  5. Honoraria $9,570 1 payment
  6. Compensation for serving as faculty or as a speaker for a medical education program $6,300 2 payments
  7. Education $97 3 payments
Products named General payments · program years 2019–2025
  1. ZEPBOUND $159,980 150 payments
  2. Wegovy $157,447 86 payments
  3. Saxenda $120,279 71 payments
  4. LigaSure $19,770 49 payments
  5. SYNECOR Biomaterial $10,005 4 payments
  6. Sonicision $7,022 12 payments
  7. Signia $6,370 77 payments
  8. LIGATION: HEMOCLIP METAL LIGATION SYSTEM $6,300 2 payments
  9. Talicia $2,775 1 payment
  10. VersaOne $2,500 1 payment
  11. Other $18,309 127 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Medtronic, Inc. $35,949 10 payments
  2. Covidien LP $14,632 4 payments

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

100

Median for General Surgery: 59

Drug cost

$1,156

Median for General Surgery: $393

Branded share of claims

0%

Median for General Surgery: 28.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Pantoprazole Sodium Generic 56 $714
Omeprazole Generic 24 $309
Metoclopramide Hcl Generic 20 $132

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 15,891 Part D prescribers listed as General Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 53 billing codes

Paid by Medicare

$33,843

Medicare's payments for the services billed

Medicare patients

89

Average age 67

Services billed

184

60 women, 29 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 54%
Depression 53%
Diabetes 31%
Chronic kidney disease 30%
Ischemic heart disease 25%
Osteoporosis 22%
Atrial fibrillation 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ZEPBOUND
  • Lilly USA, LLC $77,583
$77,583 — —
Wegovy
  • Novo Nordisk Inc $64,795
$64,795 — —
Ozempic
  • Novo Nordisk Inc $108
$108 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

827 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Surgery in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record